These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30031168)

  • 1. The use of real-world data in cancer drug development.
    Skovlund E; Leufkens HGM; Smyth JF
    Eur J Cancer; 2018 Sep; 101():69-76. PubMed ID: 30031168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evidence-What is it and does it matter for approval of drugs?
    Eaglstein WH
    J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
    [No Abstract]   [Full Text] [Related]  

  • 3. Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality.
    Miksad RA; Abernethy AP
    Clin Pharmacol Ther; 2018 Feb; 103(2):202-205. PubMed ID: 29214638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines Initiative.
    Happich M; Brnabic A; Faries D; Abrams K; Winfree KB; Girvan A; Jonsson P; Johnston J; Belger M;
    Clin Pharmacol Ther; 2020 Oct; 108(4):817-825. PubMed ID: 32301116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Giulio Formoso, per l'Associazione Alessandro Liberati - Network italiano Cochrane
    Recenti Prog Med; 2019 Nov; 110(11):524-525. PubMed ID: 31808432
    [No Abstract]   [Full Text] [Related]  

  • 6. Care to compare?
    Aston G
    Hosp Health Netw; 2008 Dec; 82(12):38-41, 1. PubMed ID: 19209502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in cancer drug assessment between Spain and the United Kingdom.
    Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
    Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The architecture of clinical research (From the "Biostatistics and Epidemiology Lecture Series, Part 1").
    Stoller JK
    Cleve Clin J Med; 2017 Sep; 84(9 Suppl 2):e2-e9. PubMed ID: 28937357
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness research in radiology.
    Hunink MG
    Acad Radiol; 1996 Apr; 3 Suppl 1():S13-6. PubMed ID: 8796498
    [No Abstract]   [Full Text] [Related]  

  • 11. Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?
    Dranitsaris G; Papadopoulos G
    Appl Health Econ Health Policy; 2015 Jun; 13(3):291-302. PubMed ID: 25274258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.
    van Nooten F; Holmstrom S; Green J; Wiklund I; Odeyemi IA; Wilcox TK
    Drug Discov Today; 2012 Jun; 17(11-12):615-22. PubMed ID: 22366662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.
    Pearce M; Hee SW; Madan J; Posch M; Day S; Miller F; Zohar S; Stallard N
    BMC Med Res Methodol; 2018 Feb; 18(1):20. PubMed ID: 29422021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating data from randomized controlled trials and observational studies to predict the response to pregabalin in patients with painful diabetic peripheral neuropathy.
    Alexander J; Edwards RA; Savoldelli A; Manca L; Grugni R; Emir B; Whalen E; Watt S; Brodsky M; Parsons B
    BMC Med Res Methodol; 2017 Jul; 17(1):113. PubMed ID: 28728577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine needs randomized clinical trials.
    Saad ED; Paoletti X; Burzykowski T; Buyse M
    Nat Rev Clin Oncol; 2017 May; 14(5):317-323. PubMed ID: 28169302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment.
    Gyawali B; Hwang TJ; Vokinger KN; Booth CM; Amir E; Tibau A
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():374-387. PubMed ID: 31099613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
    Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
    Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pragmatic randomized controlled trials as a source of data in the assessment of effectiveness of medical technology].
    Kaczyński L; Solnica B
    Przegl Lek; 2012; 69(9):703-7. PubMed ID: 23401993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
    Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
    Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
    [No Abstract]   [Full Text] [Related]  

  • 20. Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.
    Lewis JR; Kerridge I; Lipworth W
    J Clin Oncol; 2015 Dec; 33(34):4112-7. PubMed ID: 26460298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.